SynchNeuro
Category: AI in Healthcare
Non-invasive glucose monitoring technology using EEG-based brain activity analysis for cardiometabolic health monitoring SynchNeuro was founded in 2021. The company is led by Casey Halpern. Based in Philadelphia, Pennsylvania, USA. Team size: 5-50. Total funding raised: $3 million. Latest round: Seed. Key investors include Boomerang Ventures.
- Founded
- 2021
- Headquarters
- Philadelphia, Pennsylvania, USA
- Team size
- 5-50
- Total funding
- $3 million
Value proposition
Eliminates invasive blood sampling for continuous glucose monitoring, leveraging brain-metabolism correlations with predictive forecasts at $10/month subscription
Products and solutions
EEG-based continuous glucose monitor (Cardiometabolic Advisor), AI-driven glucose prediction algorithms, Rechargeable needle-free sensor worn behind the ear
Unique value
First FDA-cleared brain-based glucose monitoring system utilizing stereotactic neurosurgery principles with non-invasive EEG technology
Target customer
Diabetes patients, healthcare providers, and medical device distributors, focusing on 125 million Americans with prediabetes or non-insulin-treated Type 2 diabetes
Industries served
Medical devices, Diabetes care, Neurotechnology, Cardiometabolic health
Technology advantage
Proprietary EEG signal processing algorithms combined with deep brain stimulation expertise from Stanford University collaborations, clinical-grade glucose tracking meeting FDA thresholds
How they differentiate
SynchNeuro differentiates itself through brain-based EEG technology for non-invasive glucose monitoring, whereas competitors like Occuity use eye scans and Diawiser employs voice analysis. This approach offers a unique, consumer-friendly alternative with potential for higher accuracy in metabolic insights at a $10/month price point.
Main competitors
Occuity (UK), Diawiser (Lithuania), Abbott Laboratories, Dexcom Inc.
Key partnerships
Boomerang Ventures (seed-stage investors), Stanford University School of Medicine, University of Pennsylvania Perelman School of Medicine, Plug and Play Lifetech Batch
Notable customers
Not public
Major milestones
Development of FDA-threshold-accurate EEG-based glucose monitoring technology (2025), Seed-stage investment from Boomerang Ventures (November 2025), Selected for Plug and Play's inaugural Lifetech Batch in Indianapolis, Partnerships with academic institutions for clinical validation (Stanford University, University of Pennsylvania)
Growth metrics
Not public
Market positioning
Positioned as a pioneer in neurotechnology for healthcare, targeting diabetes management and prediabetes populations with a non-invasive, proactive monitoring solution
Geographic focus
Primary focus on the United States, with potential expansion into European markets given the global interest in non-invasive glucose monitoring
Patents and IP
US Patent pending for brain glucose state estimation via cortical activity patterns
About Casey Halpern
Neurosurgeon and researcher with expertise in brain-metabolism connections, Professor of Neurosurgery and Associate Professor at Stanford University School of Medicine, specializing in stereotactic and functional neurosurgery
Official website: https://www.synchneuro.com/